Press Conference Held in Taiwan to Announce the Results of a Phase 2 Trial of ADI‑PEG 20 in Advanced HCC

TDW Pharmaceuticals, Inc., an affiliate of Polaris in Taiwan, presented results from its sponsored trial of ADI‑PEG 20 in patients with hepatocellular carcinoma (HCC). The randomized Phase 2 trial was conducted by over 25 investigators from 10 separate medical institutions in Taiwan and funded in part by the Taiwanese government. Polaris President and CEO Bor-Wen Wu gave introductory remarks, and Principal Investigators, Dr. Li-Tzong Chen of Taiwan’s Veterans General Hospital and the Taiwan Cooperative Oncology Group, and Dr. Pei-Jer Chen of National Taiwan University Hospital, Taiwan presented the study results. Additional information was presented by John Bomalski, M.D., Vice President of Medical Affairs at Polaris, Archie Prestayko, Ph.D., Vice President of Corporate Affairs at Polaris, and by representatives of the Taiwanese government. Over 70 invited guests from the Taiwanese medical community, government, news media and investors were in attendance.

Detailed results of this trial will be presented at the upcoming ASCO Gastrointestinal Cancers Symposium to be held in San Francisco January 15-17, 2009.

About TDW Pharmaceuticals, Inc.
TDW Pharmaceuticals Inc. is a privately held biopharmaceutical company based in Taiwan, with subsidiaries in Shanghai, China and Northern California. The Northern California subsidiary, DesigneRx Pharmaceuticals has a cGMP facility and is currently responsible for producing the drug product used in the ongoing clinical trials of ADI‑PEG 20. The Shanghai subsidiary, DesigneRx (Shanghai), is a preclinical research facility that conducts in vitro testing in tumor cell lines and in vivo testing in xenograft models.

About Polaris Group
Polaris Group is a privately held multinational biopharmaceutical company specializing in the research and development of protein drugs to treat cancer and other debilitating diseases. The company also utilizes a rational structure-based approach for the design of novel small molecule inhibitors of cancer-related protein targets.